Alzheimer's disease (AD) is the most common form of dementia, and age is a major risk factor for this devastating neurodegenerative disease ([@r1]). The major pathological hallmarks of AD are the accumulation of senile plaque in the extracellular space and intraneuronal neurofibrillary tangle formation associated with excessive neuronal cell loss ([@r1][@r2]--[@r3]). Senile plaque is predominantly composed of amyloid beta (Aβ) generated from amyloid precursor protein (APP) via the amyloidogenic pathway ([@r4], [@r5]). Aβ is generated by sequential cleavage of APP by β-secretase (i.e., BACE1) and γ-secretase, with BACE1 as the rate-limiting enzyme in this process ([@r6][@r7][@r8][@r9]--[@r10]). Accumulated evidence demonstrates that BACE1 enzymatic activity increases in AD ([@r11][@r12]--[@r13]), while BACE1 mRNA and protein levels in AD remain unchanged ([@r14][@r15]--[@r16]), though there are contradictory reports indicating that BACE1 protein levels might increase ([@r17][@r18]--[@r19]).

APP cleavage by BACE1 preferentially occurs in the early or late endosomes that provide the acidic environment necessary for optimal BACE1 activity ([@r20][@r21]--[@r22]). After translation, BACE1 is modified by acetylation and N-glycosylation that might mediate BACE1 folding and enzymatic activity ([@r23], [@r24]). BACE1 is phosphorylated on S498, which mediates its intracellular trafficking ([@r7], [@r25], [@r26]). It has previously been documented that BACE1 can be ubiquitinated at K501 residue, regulating its half-life ([@r27]). The half-life of BACE1 is not greater than 12 h, allowing for substantial trafficking and activation-inactivation cycling between different subcellular compartments ([@r28][@r29]--[@r30]).

In the current study, we provide extensive in vitro and in vivo evidence demonstrating that BACE1 is SUMOylated on the same residue (K501), mediating its stability. Moreover, we show that the SUMOylation of BACE1 escalates its protease activity, resulting in augmentation of Aβ production. Accordingly, injection of wild-type BACE1, but not non-SUMOylated K501R mutant, facilitates Aβ production and accelerates senile plaque deposit and the cognitive defect associated with extensive synaptic degeneration.

Results {#s1}
=======

BACE1 Is SUMOylated at K275 and K501 Residues. {#s2}
----------------------------------------------

Our previous data demonstrate that SUMO-1 (small ubiquitinlike modifier protein 1) is highly increased in AD patients; we also reported that tau is SUMOylated in response to Aβ treatment ([@r31]). Hence, we explored whether or not BACE1 is also SUMOylated. We transfected HEK293 cells with FLAG-tagged BACE1, Myc-SUMO-1, and UBC9. Immunoprecipitation with anti-FLAG revealed that BACE1 was highly SUMOylated ([Fig. 1*A*](#fig01){ref-type="fig"}). Moreover, we made the similar observation in the neuronal cell line N2A, which is APP stably transfected. We found that endogenous BACE1 was also highly SUMOylated in the presence of UBC9 ([Fig. 1*B*](#fig01){ref-type="fig"}). One month after injection of FLAG-tagged BACE1 into wild-type C57BL/6J mice, we conducted immunoprecipitation with anti-FLAG, and found that BACE1 once again was strongly SUMOylated ([Fig. 1*C*](#fig01){ref-type="fig"}). Thus, these data suggest that BACE1 is greatly SUMOylated in the presence of UBC9.

![BACE1 is SUMOylated at K275 and K501. (*A*) FLAG-BACE1 plasmid was transfected to HEK293T cells together with the cotransfection of Myc-SUMO-1 and UBC9 for 48 h. Next, the cell lysates were immunoprecipitated (IP) using anti-FLAG and anti-Myc antibodies. The SUMOylation of BACE1 was analyzed by Western blotting (IB). (*B*) N2A/APP cells were cotransfected with FLAG-BACE1 and UBC9 for 48 h, and then the cell lysates were immunoprecipitated using anti-FLAG and anti--SUMO-1 antibodies. The endogenous SUMOylation of BACE1 was analyzed by Western blotting. (*C*) The C57BL/6J mice were infected with AAV-FLAG-BACE1 or vector (as control) into the CA1 region of the hippocampus. Homogenates of hippocampi were immunoprecipitated using anti-FLAG and anti--SUMO-1 antibodies at 1 mo after injection. The SUMOylated BACE1 was analyzed by Western blotting. (*D*) Candidate BACE1 SUMOylated sites (shown in red) were predicted using the SUMOsp2.0 Software. (*E*) Alignment of BACE1 sequence from different species showing the potential SUMO target sites (shown in red). (*F*) FLAG-BACE1 WT, FLAG-BACE1 K275R, or FLAG-BACE1 K501R plasmids were transfected to HEK293T cells together with the cotransfection of Myc-SUMO-1 and UBC9 for 48 h. Next, the cell lysates were immunoprecipitated using anti--SUMO-1 antibody. The BACE1 interaction with SUMO-1 was analyzed by Western blotting employed with anti-FLAG antibody. (*G*) FLAG-BACE1 WT, FLAG-BACE1 K275R, or FLAG-BACE1 K501R plasmids were transfected to N2A/APP cells together with UBC9 for 48 h. Next, the cell lysates were immunoprecipitated using anti--SUMO-1 antibody. The SUMOylated BACE1 was analyzed by Western blotting using anti-FLAG antibody.](pnas.1800498115fig01){#fig01}

To map the potential SUMOylation sites on BACE1, we performed SUMOylation analysis using a computer program, and found that K275 and K501 residues are potential SUMOylation sites ([Fig. 1*D*](#fig01){ref-type="fig"}). Protein alignment demonstrates that these two sites are well conserved among different species ([Fig. 1*E*](#fig01){ref-type="fig"}). As expected, mutation of either K275R or K501R evidently reduced BACE1 SUMOylation in HEK293T cells transfected with SUMO-1 and UBC9. When we employed the double K275R/501R mutant, the SUMOylation was completely abolished, indicating that K275 and K501 residues are the major SUMOylation sites on BACE1 ([Fig. 1*F*](#fig01){ref-type="fig"}). The observation was similar in N2A/APP stable cell lines in the presence of UBC9 ([Fig. 1*G*](#fig01){ref-type="fig"}). Therefore, these findings imply that BACE1 can be SUMOylated at K275 and K501 residues.

SUMOylation of BACE1 at K501 Increases Its Stability. {#s3}
-----------------------------------------------------

To compare the contribution of these two potential sites in BACE1 SUMOylation, we employed different amounts of protein lysates transfected from the individual mutant. We found that K275R mutation substantially decreased BACE1 SUMOylation, and the non-SUMOylated BACE1 amount was also reduced ([Fig. 2*A*](#fig02){ref-type="fig"}). Strikingly, K501R SUMOylation was almost completely abolished. Noticeably, non-SUMOylated BACE1 was evidently diminished. Interestingly, similar results were observed when the same membranes were stripped and reprobed with anti--SUMO-1 antibody ([Fig. 2*A*](#fig02){ref-type="fig"}). To quantitatively analyze whether SUMOylation affects the half-life of BACE1, we treated FLAG-BACE1 plus UBC9--transfected cells with the translation inhibitor cycloheximide (CHX) for different time points. Immunoblotting analyses indicated that non-SUMOylated K501R half-life was clearly reduced compared with wild-type BACE1 ([Fig. 2 *B*--*D*](#fig02){ref-type="fig"}). Again, the SUMOylated version of BACE1 was temporally attenuated in the presence of CHX ([Fig. 2 *B* and *C*](#fig02){ref-type="fig"}). By contrast, the mRNA levels between wild-type BACE1 and K501R remained comparable ([Fig. 2*E*](#fig02){ref-type="fig"}), indicating that the time-dependent reduction of BACE1 and K501R mutant is not due to different mRNA levels. Presumably, SUMOylation might delay BACE1 degradation.

![SUMOylation of BACE1 at K501 increases its stability. (*A*) FLAG-BACE1 WT or different lysine residue mutant (K275R and K501R) plasmids were transfected to N2A/APP cells with UBC9 for 48 h. SUMOylated BACE1 at around 72-kDa bands and BACE1 at around 55-kDa bands were monitored within different amounts of protein (2× loading for K275R, 5× loading for K501R), and the same membranes were stripped and blotted with anti--SUMO-1 antibody. The expression level of UBC9 was also examined with anti-UBC9 antibody. (*B* and *C*) FLAG-BACE1 WT plus UBC9 or FLAG-BACE1 K501R plus UBC9 was transfected to N2A/APP cells treated with translation inhibitor CHX (100 μg/mL) for another 2, 4, 6, and 8 h. The degradation of BACE1 was detected by Western blotting and quantitative analysis. (*D*) Half-life time of BACE1 in the presence of CHX was quantified. (*E*) The mRNA level of BACE1 was measured at 48 h after cotransfection with FLAG-BACE1 WT plus UBC9 or FLAG-BACE1 K501R plus UBC9 to N2A/APP cells by using quantitative PCR. (*F*) Immunofluorescence showed the colocalization (white arrow) of BACE1 (anti-FLAG) and lysosome (LAMP1). \*\**P* \< 0.01 vs. BACE1 WT. (Scale bar in *F*: 10 μm.)](pnas.1800498115fig02){#fig02}

To address that non-SUMOylated K501R BACE1 becomes more prone to degradation compared with wild-type BACE1, we monitored their distribution in different types of subcellular organelles. Immunofluorescence staining showed that both wild-type BACE1 and K501R occurred in the trans-Golgi network (TGN) stained with GM130 ([Fig. S1*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1800498115/-/DCSupplemental)). Notably, wild-type BACE1 mostly localized in the endosomes stained with the biomarker EEA1 ([Fig. S1*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1800498115/-/DCSupplemental)) and in plasma membrane stained with APP ([Fig. S1*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1800498115/-/DCSupplemental)). By contrast, non-SUMOylated K501R BACE1 resided in the lysosomes stained with LAMP1 for degradation ([Fig. 2*F*](#fig02){ref-type="fig"}). Together, these findings suggest that SUMOylation of BACE1 at K501 may mediate its intracellular trafficking and increase its stability.

BACE1 K501 SUMOylation Increases Its Enzymatic Activity. {#s4}
--------------------------------------------------------

BACE1 cleaves APP and releases a secreted fragment of sAPP-β. To quantitatively compare the effect of SUMOylation on BACE1 enzymatic activity, we monitored sAPP-β production in the cells transfected with wild-type BACE1 or non-SUMOylated mutant K501R. We found that sAPP-β was significantly reduced in K501R-transfected cells compared with wild-type ([Fig. 3 *A* and *B*](#fig03){ref-type="fig"}). However, it somehow increased the sAPP-β amount compared with vector control. Subsequently, we monitored the secretase Aβ~40~ and Aβ~42~ levels by ELISA in the medium. As expected, overexpressing wild-type BACE1 highly increased the levels of both Aβ~40~ and Aβ~42~. By contrast, K501R only slightly increased Aβ compared with vector control ([Fig. 3 *C* and *D*](#fig03){ref-type="fig"}). Together, these data strongly suggest that SUMOylation BACE1 at K501 enhances its protease activity and produces more Aβ.

![SUMOylation of BACE1 at K501 increases its enzymatic activity. (*A* and *B*) FLAG-BACE1 WT plus UBC9 or different lysine residue mutant (K275R and K501R) plasmids plus UBC9 were cotransfected to N2A/APP cells for 48 h; next, the secreted fragment APP-β cleaved by BACE1 and the total APP in lysate were examined by Western blotting and quantitative analysis. (*C* and *D*) The Aβ~40~ and Aβ~42~ levels in cell medium were measured by ELISA. \*\**P* \< 0.01 vs. vector; ^\#\#^*P* \< 0.01 vs. BACE1 WT.](pnas.1800498115fig03){#fig03}

BACE1 SUMOylation Induces Cognitive Impairment and Aβ Toxicity. {#s5}
---------------------------------------------------------------

Overexpression of BACE1 increases its SUMOylation and protease activity in cells. To investigate whether SUMOylation plays any role in mediating BACE1 enzymatic activity in animals, we injected wild-type BACE1 or non-SUMOylated K501R AAV2 into the hippocampus of wild-type C57BL/6J mice. In a month, we performed the Morris water maze behavior test and found that overexpressed wild-type BACE1 initiated evident cognitive dysfunction compared with vector control or non-SUMOylated K501R ([Fig. 4 *A*--*C*](#fig04){ref-type="fig"}). Nonetheless, there is no significant difference between vector control and K501R mice ([Fig. 4 *A*--*C*](#fig04){ref-type="fig"}). The swimming speed remained comparable among the groups, indicating that BACE1 or its non-SUMOylated mutant does not affect motor function ([Fig. 4*D*](#fig04){ref-type="fig"}). Immunohistochemistry (IHC) staining with MAP2 in the CA1 region (AAV injection site) of the hippocampus demonstrated that the dendrites were greatly reduced in wild-type BACE1--injected mice, but not non-SUMOylated K501R, while non-SUMOylated BACE1 remained comparable to the control ([Fig. 4 *E* and *F*](#fig04){ref-type="fig"}). By contrast, the dendrites remained similar among the groups in CA3 and dentate gyrus regions ([Fig. S2 *A*--*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1800498115/-/DCSupplemental)). The synapses were remarkably decreased in wild-type BACE1--injected mice compared with vector control or non-SUMOylated K501R mutant mice. Immunoblotting analysis revealed that the synaptic proteins, including PSD95, GluR1, synaptophysin, synapsin-1, and synaptotagmin, were all reduced in the hippocampus injected with wild-type BACE1; in contrast, non-SUMOylated K501R--injected mice remained comparable to vector control ([Fig. S2 *D*--*I*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1800498115/-/DCSupplemental)). These observations were in alignment with Golgi staining ([Fig. 4 *G*--*I*](#fig04){ref-type="fig"}) and dendrite staining results, indicating that the synapses are extensively lost in wild-type BACE1--overexpressed mice.

![BACE1 SUMOylation induces cognitive impairment and Aβ toxicity. (*A*) The bilateral hippocampus CA1 zone of 3-mo-old C57BL/6J mice was injected with AAV2-vector, AAV2-BACE1 WT, or AAV2-BACE1 K501R. In 1 mo, the mice were trained in Morris water maze for five consecutive days to measure the learning capacity. The escape latencies to find the hidden platform were recorded daily. (*B* and *C*) Memory was tested on the sixth day via removal of the hidden platform; traversing times in the target quadrant in 1 min and time to the target were calculated. (*D*) The mean swimming speed on the sixth day showed no significant difference among groups. (*E* and *F*) Compared with control (vector) mice, the BACE1 WT mice showed a marked decrease in the expression of the somatodendritic marker MAP2 in the CA1 region of the hippocampus at 1 mo after infection of AAV, while no difference was seen in BACE1 K501R mice. (Scale bar in *E*: 200 μm.) (*G*) Representative dendritic spines in the hippocampus CA1 region by Golgi staining. (Scale bar: 5 μm.) (*H* and *I*) The quantification for the density of dendritic spines or mushroom spines from randomly selected dendritic segments of neurons. (*J*) The protein levels of BACE1, APP-β, APP, and insulin-degrading enzyme (IDE) from hippocampal homogenates at 1 mo after injection of AAV were examined by Western blotting. (*K* and *L*) Quantitative analysis for BACE1 level at around 55-kDa and 72-kDa bands (*K*), and the ratio of APP-β to APP (*L*). (*M*) IHC with the anti-Aβ antibody 6E10 showed Aβ aggregation in the hippocampus (Hipp) and the CA1 region. (*Upper* row scale bar: 4 mm; *Lower* row scale bar: 200 μm.) (*N* and *O*) The Aβ~40~ and Aβ~42~ levels in the hippocampus were measured by ELISA. \*\**P* \< 0.01 vs. vector; ^\#\#^*P* \< 0.01 vs. BACE1 WT. MFI, mean fluorescence intensity.](pnas.1800498115fig04){#fig04}

Next, we compared the expression levels of injected wild-type BACE1 and K501R. Surprisingly, we found wild-type BACE1 levels at around 55 kDa and 72 kDa, which were highly increased compared with K501R, indicating that its SUMOylation might regulate its stability ([Fig. 4 *J* and *K*](#fig04){ref-type="fig"}). Accordingly, sAPP-β was substantially increased in wild-type BACE1--overexpressed mice compared with the control and non-SUMOylated K501R samples ([Fig. 4 *J* and *L*](#fig04){ref-type="fig"}). It is worth noting that insulin-degrading enzyme, which cleaves Aβ, remained constant among all of these samples, suggesting that Aβ accumulation is not due to its degradative enzyme alteration in response to BACE1 expression ([Fig. 4*J*](#fig04){ref-type="fig"}). To validate the injected BACE1 K501R expression level, we performed IHC staining. As expected, the FLAG-tagged K501R signal was markedly reduced compared with wild-type BACE1 ([Fig. S2*J*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1800498115/-/DCSupplemental)). IHC study with the anti-Aβ antibody 6E10 also supported that Aβ was highly aggregated in wild-type BACE1--injected mice compared with vector control or non-SUMOylated K501R ([Fig. 4*M*](#fig04){ref-type="fig"}). To further study the alteration of Aβ production under wild-type BACE1 and K501R AAV transfection, we quantitatively analyzed Aβ levels, and found that Aβ~40~ and Aβ~42~ were prominently increased in wild-type BACE1--overexpressed mice compared with the control and non-SUMOylated K501R samples ([Fig. 4 *N* and *O*](#fig04){ref-type="fig"}). Thus, these data strongly support that BACE1 SUMOylation increases its stability and augments Aβ production compared with non-SUMOylated mutant, and that BACE1 SUMOylation aggravates Aβ toxicity and escalates cognitive impairment.

Non-SUMOylated BACE1 Mutant Decreases Aβ Deposition and Cognitive Impairment in APP/PS1 Mice. {#s6}
---------------------------------------------------------------------------------------------

To assess whether BACE1 SUMOylation plays any role in AD pathologies, we employed an APP/PS1 AD mouse model. Firstly, to investigate whether BACE1 SUMOylation is age-dependently regulated in the AD mouse model, we collected brain samples from different ages of APP/PS1 mice and incubated them with the deSUMOylation inhibitor *N*-ethylmaleimide-crystalline (NEM). We found that BACE1 (with ∼55-kDa bands) and SUMOylated BACE1 (with ∼72-kDa bands) were up-regulated in an age-dependent manner; by contrast, in the absence of deSUMOylation inhibitor, BACE1 SUMOylation was obviously reduced ([Fig. 5 *A* and *B*](#fig05){ref-type="fig"}). To further validate this observation, we performed immunoprecipitation with anti--SUMO-1 or anti-BACE1 antibody, and found that BACE1 SUMOylation was escalated in an age-dependent way ([Fig. 5 *C* and *D*](#fig05){ref-type="fig"}). IHC study also supported that BACE1 SUMOylation was age-dependently up-regulated. Interestingly, BACE1 and SUMO-1 are tightly colocalized in CA1 hippocampal neurons in 12-mo-old APP/PS1 mice ([Fig. 5*E*](#fig05){ref-type="fig"}). As expected, Aβ deposit with thioflavin S staining was also age-dependently escalated in the APP/PS1 mouse hippocampal region ([Fig. 5*F*](#fig05){ref-type="fig"}). In accordance with these observations, MAP2 IHC study indicated the dendrites were also temporally reduced in the hippocampus ([Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1800498115/-/DCSupplemental)).

![Non-SUMOylated BACE1 mutant decreases Aβ deposition and cognitive impairment in APP/PS1 mice. (*A*) Hippocampal homogenates from 3- to 12-mo-old APP/PS1 mice were incubated with or without 20 nM deSUMOylation inhibitor (i.e., NEM) for Western blotting (IB) with anti-BACE1 antibody. (*B*) Quantitative analysis for BACE1 with around 55-kDa bands and SUMOylated BACE1 with around 72-kDa bands. ^♣^*P* \< 0.05 vs. 3 mo + NEM; ^♣♣^*P* \< 0.01 vs. 3 mo + NEM; ^Δ^*P* \< 0.05 vs. 12 mo + NEM. (*C* and *D*) Hippocampal homogenates were immunoprecipitated (IP) using anti--SUMO-1 and anti-BACE1 antibodies. The SUMOylated BACE1 was analyzed by Western blotting and quantification. ^♦^*P* \< 0.05 vs. 3 mo + NEM. (*E*) Double staining of SUMO-1 (white arrow) and BACE1 (white arrow) in the hippocampal CA1 region of 3- and 12-mo-old APP/PS1 mice. (Scale bar: 75 μm.) (*F*) Immunofluorescence with thioflavin S showed amyloid plaques in the CA region of the hippocampus from 3- to 12-mo-old APP/PS1 mice. (Scale bar: 200 μm.) (*G* and *H*) The bilateral hippocampal CA1 zone of 4-mo-old APP/PS1 mice was injected with AAV2-Vector, AAV2-BACE1 WT, or AAV2-BACE1 K501R. In 1 mo, mice were tested with contextual fear conditioning 1 h and 24 h after the training session. BACE1 WT--treated APP/PS1 mice exhibited significant lower freezing behavior compared with control and BACE1 K501R mice, indicating learning and memory deficit. (*I*) Immunofluorescence with thioflavin S showed amyloid plaques in the CA 1 region of the hippocampus at 1 mo after infection of AAV-Vector, AAV-BACE1WT, or AAV-BACE1K501R. (Scale bar: 200 μm.) (*J*) Quantitative analysis of amyloid plaques using thioflavin S. \*\**P* \< 0.01 vs. vector; ^\#\#^*P* \< 0.01 vs. BACE1 WT.](pnas.1800498115fig05){#fig05}

To explore whether BACE1 SUMOylation regulates the cognitive functions in the APP/PS1 AD mouse model, we injected AAV2-BACE1 WT (wild-type) or AAV2- BACE1 K501R into the hippocampus and performed the fear-conditioning experiment to monitor its effect in the cognitive function. Wild-type BACE1--injected mice revealed greatly reduced memory compared with the control or non-SUMOylated mutant ([Fig. 5 *G* and *H*](#fig05){ref-type="fig"}). In 4-mo-old APP/PS1 mice, overexpression of wild-type BACE1 facilitated amyloid deposit compared with vector control; however, non-SUMOylated BACE1 mutant mice barely increased senile plaque formation in the hippocampus ([Fig. 5 *I* and *J*](#fig05){ref-type="fig"}). Together, these data strongly suggest that BACE1 SUMOylation escalates Aβ deposition and cognitive impairment in APP/PS1 mice.

Discussion {#s7}
==========

In the current study, we provide extensive evidence supporting that BACE1 is SUMOylated in neuronal cell lines and in an AD mouse model. We found that K275 and K501 residues are the major SUMOylation sites on BACE1. Interestingly, K501 SUMOylation is required for BACE1 stability. It is worth noting that SUMOylation of BACE1 at K501 highly increases its enzymatic activity, resulting in Aβ-production escalation in the AD brain. Overexpression of wild-type BACE1, but not non-SUMOylated K501R, in wild-type mice and in the APP/PS1 AD mice model highly increases Aβ production. Moreover, the synapses and dendrites are decreased in wild-type BACE1--injected mice, but not in non-SUMOylated mutant. In alignment with these observations, the behavior studies demonstrate that overexpression of wild-type BACE1 elicits cognitive dysfunction in wild-type mice, and facilitates amyloid deposit and cognitive impairment in APP/PS1 mice.

BACE1 undergoes a complex set of posttranslational modifications during its maturation ([@r32][@r33]--[@r34]). After synthesis, BACE1 predominantly resides in the endoplasmic reticulum and then is transported to the TGN where the majority of it resides ([@r35], [@r36]). From the TGN, BACE1 is transported to the plasma membrane, and then it is endocytosed in the early and late endosomes ([@r28], [@r37]). From the endocytotic compartment, BACE1 can be recycled back to the cell surface, or it can be transited to the lysosome for degradation or go back to the TGN where it can be trafficked back to the plasma membrane ([@r19], [@r38][@r39]--[@r40]). Previous studies suggested that K501 could be ubiquitinated on BACE1 ([@r41]). The final degradation of BACE1 is proposed to occur either via transit to the late endosome-lysosome system ([@r38], [@r40]) or via the ubiquitin-proteasome system ([@r42]). Here we show that K501 is the major SUMOylation site. Moreover, we proved K501 SUMOylation is important for BACE1 stability. Presumably, ubiquitination and SUMOylation on the same residue of K501 in BACE1 might compete with each other to mediate the stability of BACE1 and regulate its half-life. In the present study, we found that SUMOylation delays BACE1 degradation. Moreover, immunofluorescence results showed non-SUMOylated K501R BACE1 is prone to localization in the lysosome for degradation. The BACE1 cleaving of APP occurs preferentially in the endosomes, which provide the optimal conditions for maximal BACE1 enzymatic activity, but can also occur at the plasma membrane ([@r22]). Hence, cell trafficking of BACE1 regulates its activity and Aβ production. Previous studies indicated that BACE1 trafficking and enzymatic activity depends on acetylation or N-glycosylation ([@r24], [@r43], [@r44]). Further, phosphorylation of Ser^498^ also plays some role in both BACE1 maturation and intracellular trafficking through the TGN and endosome systems ([@r25], [@r26], [@r45]).

It has also been reported that some proteins directly interact with BACE1 and mediate its enzymatic activity and biological functions ([@r46][@r47][@r48]--[@r49]). Moreover, they could intermediate BACE1 trafficking and lipid microdomain distribution ([@r50]). It remains unknown at this moment whether SUMOylation at K501 regulates BACE1 binding activity with different binding partners, including APP. We previously reported that SUMOylation is enhanced in AD patients' brains ([@r31]) and that Aβ treatment increases SUMOylation and augments tau SUMOylation, which subsequently elevates its half-life and escalates its aggregation, leading to its neurotoxicity enhancement ([@r31]). Here, we demonstrate that BACE1 SUMOylation augments its stability and enzymatic activity, resulting in Aβ production up-regulation. Conceivably, SUMOylation abnormality in AD might regulate numerous major pathological players, including tau and BACE1, and mediate its pathogenesis.

Materials and Methods {#s8}
=====================

Plasmids, Viruses, Chemicals, and Antibodies. {#s9}
---------------------------------------------

The plasmids encoding FLAG-tagged full-length BACE1 or His-tagged full-length SUMO-1 were generated in our laboratory. Mutation of BACE1 lysine 275 or 501 into arginine (K275R or K501R) was carried out using the QuikChange site-directed mutagenesis kit by following the manufacturer's instructions (GeneChem). All plasmids were sequenced and prepared using an endotoxin-free plasmid extraction kit (Tiangen). AAV-pCAG-FLAG-BACE1WT and AAV-pCAG-FLAG-BACE1K501R were constructed and packaged by Obio Technology Co., Ltd. Lipofectamine 2000 (Invitrogen) transfection reagents were from Invitrogen. NEM was purchased from Sigma. CHX was from Merck KGaA. Bicinchoninic acid protein detection kit was from Pierce. Reagents for cell culture were from Gibco BRL. Antibodies employed in this study are listed in [Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1800498115/-/DCSupplemental).

Cell Culture, Transfection, and Drug Treatment. {#s10}
-----------------------------------------------

The human embryonic kidney 293 (HEK293T) cells were cultured in DMEM supplemented with 10% FBS (Gibco BRL), and mouse neuroblastoma N2A cells with stable expression of APP (N2A/APP) were cultured in DMEM supplemented with 10% FBS and 200 mg/mL G418. The cells were maintained at 37 °C in a humidified atmosphere containing 5% CO~2~. Cells were seeded in a 6- or 12-well culture plate overnight and cotransfected with the mixture containing a total of 1.8 μg of plasmids and 4 μL of Lipofectamine 2000 according to the manufacturer's protocols. To explore the effect of BACE1 SUMOylation on degradation, the cells were treated with 100 μg/mL CHX for different times.

Other Methods. {#s11}
--------------

[*SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1800498115/-/DCSupplemental) includes details regarding RNA extraction, reverse transcription, quantitative real-time PCR, Aβ plaque histology, Golgi staining, stereotaxic injection of the virus, mice brain tissue preparation and protein extraction, IHC and confocal microscopy, Morris water maze, fear conditioning, immunoprecipitation, Western blot analysis, and ELISA quantification of Aβ. All animal experiments were approved by the Animal Care and Use Committee of Huazhong University of Science and Technology, and performed in compliance with the National Institutes of Health *Guide for the Care and Use of Laboratory Animals* ([@r51]).

Statistical Analysis. {#s12}
---------------------

Data were analyzed using SPSS 18.0 statistical software. All of the quantitative data are presented as mean ± SD. Statistical analysis was performed using either Student's *t* test (two groups) or one-way analysis of variance (more than two groups), followed by post hoc comparison; differences with *P* \< 0.05 were considered as statistically significant.
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